Last Updated: 09/28/21
Clinical Trials List
These are the trials that are currently offered at our clinic.
Tumor Type
All Cancer Types
- Testing the Addition of an Anti-cancer Drug, BAY1895344, to the Usual Chemotherapy Treatment (Cisplatin, or Cisplatin and Gemcitabine) for Advanced Solid Tumors with Emphasis on Urothelial Cancer
- Phase I Trial of the Combination of Bortezomib and Clofarabine in Adults with Refractory Solid Tumors
- Phase I Trial of the Combination of Nilotinib and Paclitaxel in Adults with Refractory Solid Tumors
- Molecular Analysis for Therapy Choice (MATCH)
- A Phase I Study of Indenoisoquinoline LMP744 in Adults With Relapsed Solid Tumors and Lymphomas
- DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors
- Phase I Study of Recombinant Interleukin 15 in Combination With Checkpoint Inhibitors Nivolumab and Ipilimumab in Subjects with Refractory Cancers
- Phase I Trial of 5-aza-4'-thio-2'-deoxycytidine (Aza-TdC) in Patients With Advanced Solid Tumors
- Durvalumab in Combination with Chemotherapy in Treating Patients with Advanced Solid Tumors (DURVA+ Study)
- First-in-Human Phase I Trial to Investigate the Safety, Tolerability, Pharmacokinetics, Biological and Clinical Activity of Metarrestin (ML-246) in Subjects with Metastatic Solid Tumors
Sarcoma
- Testing the Anti-cancer Drug, Rogaratinib (BAY 1163877), for Treatment of Advanced Sarcoma with Alteration in Fibroblast Growth Factor Receptor (FGFR 1-4), and in Patients with SDH-deficient Gastrointestinal Stromal Tumor (GIST)
- A Phase 2 Study of Anti-PD-L1 Antibody (Atezolizumab) in Alveolar Soft Part Sarcoma
- SARC031: MEK Inhibitor Selumetinib (AZD6244) in Combination with the mTOR Inhibitor Sirolimus for Patients with Malignant Peripheral Nerve Sheath Tumors
- A Phase 2 Study of Anti-PD-L1 Antibody (Atezolizumab) in Chondrosarcoma and Clear Cell Sarcoma
Lymphoma
- Phase I Trial of the Combination of Bortezomib and Clofarabine in Adults with Refractory Solid Tumors
- Phase I Trial of the Combination of Nilotinib and Paclitaxel in Adults with Refractory Solid Tumors
- Molecular Analysis for Therapy Choice (MATCH)
- A Phase I Study of Indenoisoquinoline LMP744 in Adults With Relapsed Solid Tumors and Lymphomas
Rare Tumors
- Testing the Addition of an Anti-cancer Drug, BAY1895344, to the Usual Chemotherapy Treatment (Cisplatin, or Cisplatin and Gemcitabine) for Advanced Solid Tumors with Emphasis on Urothelial Cancer
- Testing the Anti-cancer Drug, Rogaratinib (BAY 1163877), for Treatment of Advanced Sarcoma with Alteration in Fibroblast Growth Factor Receptor (FGFR 1-4), and in Patients with SDH-deficient Gastrointestinal Stromal Tumor (GIST)
- A Phase I Trial of TRC102 (methoxyamine HCl) in Combination with Temozolomide in Patients with Relapsed Granulosa Cell of the Ovary and Non-small Cell Lung Cancer
- A Phase 2 Study of Anti-PD-L1 Antibody (Atezolizumab) in Alveolar Soft Part Sarcoma
- Phase II Trial of the MEK1/2 Inhibitor Selumetinib (AZD6244 hydrogen sulfate) in Adults with Neurofibromatosis Type 1 (NF1) and Inoperable Plexiform Neurofibromas
- DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors
- SARC031: MEK Inhibitor Selumetinib (AZD6244) in Combination with the mTOR Inhibitor Sirolimus for Patients with Malignant Peripheral Nerve Sheath Tumors
- Rapid Analysis and Response Evaluation of Combination Anti-Neoplastic Agents in Rare Tumors (RARE CANCER) Trial: RARE 1 Nilotinib and Paclitaxel
Trial Type
Immunotherapy
- DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors
- A Phase 2 Study of Anti-PD-L1 Antibody (Atezolizumab) in Alveolar Soft Part Sarcoma
- Phase I Study of Recombinant Interleukin 15 in Combination With Checkpoint Inhibitors Nivolumab and Ipilimumab in Subjects with Refractory Cancers
- Durvalumab in Combination with Chemotherapy in Treating Patients with Advanced Solid Tumors (DURVA+ Study)
- Nivolumab in Treating Patients with Autoimmune Disorders and Advanced, Metastatic, or Unresectable Cancer
Precision Medicine
- Pilot Study of DS-8201a Pharmacodynamics in Patients with HER2-expressing Advanced Solid Tumors
- Molecular Analysis for Therapy Choice (MATCH)
- Phase II Trial of the MEK1/2 Inhibitor Selumetinib (AZD6244 hydrogen sulfate) in Adults with Neurofibromatosis Type 1 (NF1) and Inoperable Plexiform Neurofibromas
- A Pharmacodynamics-Driven Trial of Talazoparib, an Oral PARP Inhibitor, in Patients With Advanced Solid Tumors and Aberrations in Genes Involved in DNA Damage Response
Trial Phase
Phase 1
- Testing the Addition of an Anti-cancer Drug, BAY1895344, to the Usual Chemotherapy Treatment (Cisplatin, or Cisplatin and Gemcitabine) for Advanced Solid Tumors with Emphasis on Urothelial Cancer
- Phase I Trial of the Combination of Bortezomib and Clofarabine in Adults with Refractory Solid Tumors
- Phase I Trial of the Combination of Nilotinib and Paclitaxel in Adults with Refractory Solid Tumors
- A Phase I Study of Indenoisoquinoline LMP744 in Adults With Relapsed Solid Tumors and Lymphomas
- Phase I Study of Recombinant Interleukin 15 in Combination With Checkpoint Inhibitors Nivolumab and Ipilimumab in Subjects with Refractory Cancers
- Phase I Trial of 5-aza-4'-thio-2'-deoxycytidine (Aza-TdC) in Patients With Advanced Solid Tumors
- First-in-Human Phase I Trial to Investigate the Safety, Tolerability, Pharmacokinetics, Biological and Clinical Activity of Metarrestin (ML-246) in Subjects with Metastatic Solid Tumors
- A Phase 1 Study of AZD8186 in Combination with Docetaxel in patients with PTEN mutated or PIK3CB mutated advanced solid tumors, potentially amenable to docetaxel
- Nivolumab in Treating Patients with Autoimmune Disorders and Advanced, Metastatic, or Unresectable Cancer
Phase 2
- Testing the Anti-cancer Drug, Rogaratinib (BAY 1163877), for Treatment of Advanced Sarcoma with Alteration in Fibroblast Growth Factor Receptor (FGFR 1-4), and in Patients with SDH-deficient Gastrointestinal Stromal Tumor (GIST)
- Pilot Study of DS-8201a Pharmacodynamics in Patients with HER2-expressing Advanced Solid Tumors
- A Phase I Trial of TRC102 (methoxyamine HCl) in Combination with Temozolomide in Patients with Relapsed Solid Tumors and Lymphomas
- Molecular Analysis for Therapy Choice (MATCH)
- DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors
- A Phase 2 Study of Anti-PD-L1 Antibody (Atezolizumab) in Alveolar Soft Part Sarcoma
- Phase II Trial of the MEK1/2 Inhibitor Selumetinib (AZD6244 hydrogen sulfate) in Adults with Neurofibromatosis Type 1 (NF1) and Inoperable Plexiform Neurofibromas
- Rapid Analysis and Response Evaluation of Combination Anti-Neoplastic Agents in Rare Tumors (RARE CANCER) Trial: RARE 1 Nilotinib and Paclitaxel
- A Phase 2 Study of Anti-PD-L1 Antibody (Atezolizumab) in Chondrosarcoma and Clear Cell Sarcoma
- A Pharmacodynamics-Driven Trial of Talazoparib, an Oral PARP Inhibitor, in Patients With Advanced Solid Tumors and Aberrations in Genes Involved in DNA Damage Response
- A Phase II Basket Trial of Glutaminase Inhibitor (BEGIN) CB-839 HCL in Patients with NF1 Aberrations, NF1 Mutant Malignant Peripheral Nerve Sheath Tumors (MPNST), KEAP1/NRF2 and LKB1
Clinical Trials Questions?
General Cancer Questions?